News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency

September 12, 2023

Stockholm, Sweden, September 12, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that the Company, as part of its initiatives to increase disease awareness about MCT8 deficiency, will participate at the following medical conferences during the remainder of 2023:

45th Annual Meeting of the ETA (European Thyroid Association)
September 10-13, 2023 in Milan, Italy
60th ESPE Annual Meeting (European Society of Pediatric Endocrinology)
September 21-23, 2023 in The Hague, The Netherlands
92nd Annual Meeting of the American Thyroid Association
September 27- October 1, 2023 in Washington DC, USA
CNS – 52nd Child Neurology Society Annual Meeting
October 4-7, 2023 in Vancouver, BC, Canada
Recently, the Company also presented a poster at the
SSIEM – Society for the Study of Inborn Errors of Metabolism
August 29- September 1, 2023 in Jerusalem, Israel
The poster entitled “Landscape of genetic testing for monocarboxylate transporter 8 (MCT8) deficiency” can be found here.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10